Superior Patient Care with Proven Outcomes

Barricaid, a groundbreaking bone-anchored annular closure device backed by over a decade of clinical research, helps surgeons preserve more of the native disc, reducing the risk of reherniation, reoperations, and early readmissions following discectomy.
HEAR FROM PEERS

THE DISCECTOMY DILEMMA

For decades, spine surgeons have encountered a discectomy dilemma: whether to perform an aggressive discectomy, which reduces the risk of reherniation but may increase the likelihood of long-term back and leg pain, or to opt for a conservative discectomy, which preserves more disc tissue but carries a higher risk of reherniation. Barricaid enables surgeons to preserve more of the native disc and prevent reoperation for reherniation by 81% in high-risk patients.1

AT-RISK PATIENTS OFTEN HAVE DISCS WORTH SAVING

In a meta-analysis which includes 1,650+ patients2, it was found that large defects (>6mm) have:

  • 2.5x risk of reherniation
  • 2.3x risk of reoperation

>40% of disc herniations come from large defects3

73%

of all reoperations come from
high-risk patient population4

Patients who receive
a second surgery see
worse results.

53% receive fusions5

88% using opioids and at higher doses6

42% not working5

BARRICAID: A BIOMECHANICAL SOLUTION

Pressure in the lumbar disc has been measured as high as 334 PSI (10x average car tire pressure!)8. Unlike previous devices that have tried to solve this problem, Barricaid anchors to bone and is designed to close the annular defect from the inside, repressurizing the disc and preventing recurrence.

  • Flexible polymer component designed to plug hole from inside annulus
  • Titanium bone anchor prevents migration
  • Maintains motion
  • Does not impact future surgical options

MEASURE

TRIAL

IMPLANT

BARRICAID IS ONE OF THE MOST STUDIED DEVICES IN SPINE

Barricaid has been used to treat over 13,000 patients and is backed by 70+ peer reviewed publications.

Lequin 2012
  • Prospective, single arm, 12 months
  • 45 subjects
  • 2.4% reherniation rate
  • No device complications
Vukas 2013
  • Prospective, single arm, 2 years
  • 30 subjects
  • 0% reherniation rate
  • No device complications
Cho 2019
  • 2 year RCT
  • 30 Barricaid/30 Control
  • 5% vs 28.6% reherniation rate
  • No device complications

BARRICAID IS ONE OF THE MOST STUDIED DEVICES IN SPINE

Sponsored and Non-sponsored RCTs, and multiple Level 1A Meta-Analyses

  • 70+ peer reviewed publications
  • Safety, efficacy, durability and health economics
  • Proven superior vs. discectomy alone: significant reduction in reherniations, reoperations, and readmissions

81%

reduction in
reoperations for
reherniations*

PUBLISHED 5 YEAR RCT: THOME 2021

BARRICAID IS PROVEN TO BE DURABLE AND
NOT LIMIT FUTURE REOPERATION OPTIONS

Kursumovic 2017

  • 6-year real-world evidence
  • Single arm, 171 subjects
  • 3.5% reherniation rate

Wang 2023

  • Prospective, single arm, 2 years
  • 30 subjects
  • 0% reherniation rate
  • No device complications

Klassen 2019

  • 554 Patient RCT
  • Reoperation choices, complications, and outcomes not impacted by Barricaid

Thome 2021

  • 5 Year RCT
  • Maintenance of benefits

HEAR FROM YOUR PEERS

  • 1. Some studies outside US indications. Values at min 1 yr post-op. Minimum study size of 20 Barricaid subjects
  • 2. Spine - Miller, 2018
  • 3. FREEDOM Registry Data
  • 4. J Bone Surg. Am. 2003- Carragee, et al
  • 5. J.clineuor 2018 - Kerezoudis
  • 6. Spine 2017 - O’Donnell J et al.
  • 7. Clinicoecon Outcomes Res 2018 - Klassen
  • 8. Wilke, 1999

If Barricaid is right for you, we can help.

Sign up to receive future updates and information on the Barricaid procedure.
  • This field is for validation purposes and should be left unchanged.

WordPress Lightbox Plugin